Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 3985-3989

  Sjölund Karlsson, Maria ^a   Joyce, Kevin ^a   Blickenstaff, Karen ^b   Ball, Takiyah ^c   Haro, Jovita ^c   Medalla, Felicita M ^a   Fedorka Cray, Paula ^c   Zhao, Shaohua ^b   Crump, John A ^a   Whichard, Jean M ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AZITHROMYCIN; CEFOXITIN; CEFTIOFUR; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; GENOMIC DNA; GENTAMICIN; KANAMYCIN; NALIDIXIC ACID; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; COLONY FORMING UNIT; CONTROLLED STUDY; ESCHERICHIA COLI; GENETIC ASSOCIATION; MEAT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALMONELLA ENTERICA; SEROTYPE; STAPHYLOCOCCUS AUREUS; UNITED STATES; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; SALMONELLA ENTERICA; UNITED STATES;

EID: 80051812919     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00590-11     Document Type: Article

References (38)

1. Al Naiemi, N., et al. 2008. Extended-spectrum-beta-lactamase production in a Salmonella enterica serotype Typhi strain from the Philippines. J. Clin. Microbiol. 46:2794-2795.
2. American Academy of Pediatrics. 2009. Shigella infections, p. 584-589, 593-596. In L. K. Pickering (ed.), Red Book: 2009 report of the Committee on Infectious Diseases, 28th ed. American Academy of Pediatrics, Elk Grove Village, IL.
3. Butler, T., et al. 1999. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J. Antimicrob. Chemother. 44:243-250. (Pubitemid 29389288)
4. Chinh, N T, et al. 2000. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob. Agents Chemother. 44:1855-1859. (Pubitemid 30422937)
5. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters, 3rd ed. Approved standard. CLSI M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Crump, J A, et al. 2008. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: A United States FoodNet multicenter retrospective cohort study. Antimicrob. Agents Chemother. 52:1278-1284. (Pubitemid 351521988)
9. Crump, J A, and E D Mintz. 2010. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50:241-246.
10. DuPont, H L 2009. Clinical practice. Bacterial diarrhea. N. Engl. J. Med. 361:1560-1569.
11. European Committee on Antimicrobial Susceptibility Testing. 2011. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/ EUCAST-breakpoints-v1.3-pdf.pdf.
12. Folster, J P, R. Rickert, E J Barzilay, and J M Whichard. 2009. Identification of the aminoglycoside resistance determinants armA and rmtC among non-Typhi Salmonella isolates from humans in the United States. Antimicrob. Agents Chemother. 53:4563-4564.
13. Frenck, R W, Jr., et al. 2004. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin. Infect. Dis. 38:951-957.
14. Frenck, R W, Jr., et al. 2000. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin. Infect. Dis. 31:1134-1138. (Pubitemid 32297618)
15. Girgis, N I, et al. 1999. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob. Agents Chemother. 43:1441-1444. (Pubitemid 29259340)
16. Guerrant, R L, et al. 2001. Practice guidelines for the management of infectious diarrhea. Clin. Infect. Dis. 32:331-351. (Pubitemid 32173618)
17. Gunell, M., et al. 2010. In vitro Activity of azithromycin against nontyphoidal Salmonella enterica. Antimicrob. Agents Chemother. 54:3498-3501.
18. Hohmann, E L 2001. Nontyphoidal salmonellosis. Clin. Infect. Dis. 32:263-269. (Pubitemid 32524797)
19. Howie, R L, J P Folster, A. Bowen, E J Barzilay, and J M Whichard. 2010. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb. Drug Resist. 16:245-248.
20. Kahlmeter, G, and D. Brown. 2004. Harmonization of antimicrobial breakpoints in Europe - can it be achieved? Clin. Microbiol. Newsl. 26:187-192. (Pubitemid 40142649)
21. Kahlmeter, G., et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148. (Pubitemid 36986868)
22. Keddy, K H, A M Smith, A. Sooka, H. Ismail, and S. Oliver. 2010. Fluoroquinolone-resistant typhoid, South Africa. Emerg. Infect. Dis. 16:879-880.
23. Lalak, N J, and D L Morris. 1993. Azithromycin clinical pharmacokinetics. Clin. Pharmacokinet. 25:370-374. (Pubitemid 23327922)
24. Lynch, M F, et al. 2009. Typhoid fever in the United States, 1999-2006. JAMA 302:859-865.
25. Maskey, A P, et al. 2008. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans. R. Soc. Trop. Med. Hyg. 102:91-95. (Pubitemid 350177431)
26. Molloy, A., et al. 2010. First report of Salmonella enterica serotype Paratyphi A azithromycin resistance leading to treatment failure. J. Clin. Microbiol. 48:4655-4657.
27. Nordmann, P., et al. 2008. Multidrug-resistant Salmonella strains expressing emerging antibiotic resistance determinants. Clin. Infect. Dis. 46:324-325.
28. Ojo, K K, et al. 2004. The mef(A) gene predominates among seven macrolide resistance genes identified in gram-negative strains representing 13 genera, isolated from healthy Portuguese children. Antimicrob. Agents Chemother. 48:3451-3456. (Pubitemid 39129344)
29. Panteix, G., et al. 1993. In-vitro concentration of azithromycin in human phagocytic cells. J. Antimicrob. Chemother. 31(Suppl. E):1-4. (Pubitemid 23220182)
30. Parry, C M, et al. 2007. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob. Agents Chemother. 51:819-825. (Pubitemid 46355261)
31. Parry, C M, and E J Threlfall. 2008. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr. Opin. Infect. Dis. 21:531-538.
32. Pokharel, B M, et al. 2006. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: Surveillance of resistance and a search for newer alternatives. Int. J. Infect. Dis. 10:434-438. (Pubitemid 44633751)
33. Roberts, M C 2008. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol. Lett. 282:147-159. (Pubitemid 351569469)
34. Scallan, E., et al. 2011. Foodborne illness acquired in the United States - major pathogens. Emerg. Infect. Dis. 17:7-15.
35. Turnidge, J, and D L Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408. (Pubitemid 47175010)
36. Whichard, J M, et al. 2007. Human Salmonella and concurrent decreased susceptibility to quinolones and extended-spectrum cephalosporins. Emerg. Infect. Dis. 13:1681-1688. (Pubitemid 350126195)
37. World Health Organization. 2005. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. http://www.searo.who.int/LinkFiles/CAH-Publications-shigella.pdf.
38. World Health Organization. 2005. The treatment of diarrhoea: a manual for physicians and other senior health workers, 4th rev. http://whqlibdoc.who.int/ publications/2005/9241593180.pdf.